G1 Therapeutics Shares Conclude Trading Following Acquisition

The publicly traded journey of G1 Therapeutics has reached its conclusion. The biotechnology firm ceased trading on the NASDAQ effective September 18, 2024, following its acquisition by Pharmacosmos A/S. This corporate action finalizes the investment timeline for shareholders.

Acquisition Terms and Market Exit

Pharmacosmos Therapeutics, a Danish pharmaceutical company, secured all outstanding G1 Therapeutics shares in a transaction valued at approximately $405 million. The acquisition price was set at $7.15 per share, representing a significant premium compared to pre-announcement trading levels.

The tender offer succeeded with approximately 75% of shares tendered. Subsequent to the acquisition, G1 Therapeutics merged with a subsidiary of Pharmacosmos, resulting in its delisting from the public market. The company’s trading symbol, GTHX, has been permanently retired from exchange listings.

Should investors sell immediately? Or is it worth buying G1 Therapeutics?

Shareholder Implications and Future Operations

For equity holders, the G1 Therapeutics investment chapter is now complete. The company’s shares no longer exist as a publicly traded security, eliminating future quarterly financial reports and analyst coverage. Market researchers have already removed the company from their active monitoring lists.

The former biotechnology entity now functions as a wholly-owned subsidiary under Pharmacosmos Therapeutics. Future development of its oncology treatment portfolio, including the myeloprotective agent COSELA, falls entirely under the purview of the new corporate parent.

The aspiration for a breakthrough biotechnology investment outcome has concluded for G1 Therapeutics shareholders.